NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$275.1m

Last Updated

2021/04/11 10:21 UTC

Data Sources

Company Financials

Executive Summary

PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mailand China, and internationally. More Details


Snowflake Analysis

Undervalued with mediocre balance sheet.

Share Price & News

How has PuraPharm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1498 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1498's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

1.4%

1498

0.8%

HK Pharmaceuticals

-1.1%

HK Market


1 Year Return

-10.3%

1498

21.2%

HK Pharmaceuticals

28.6%

HK Market

Return vs Industry: 1498 underperformed the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.

Return vs Market: 1498 underperformed the Hong Kong Market which returned 28.6% over the past year.


Shareholder returns

1498IndustryMarket
7 Day1.4%0.8%-1.1%
30 Day1.4%0.7%-1.8%
90 Day2.9%10.0%3.4%
1 Year-10.3%-10.3%23.0%21.2%33.5%28.6%
3 Year-71.5%-73.1%-14.3%-19.1%4.0%-6.9%
5 Year-78.2%-80.0%79.2%62.4%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is PuraPharm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PuraPharm undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1498 (HK$0.7) is trading below our estimate of fair value (HK$1.71)

Significantly Below Fair Value: 1498 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1498 is good value based on its PE Ratio (8.2x) compared to the HK Pharmaceuticals industry average (12x).

PE vs Market: 1498 is good value based on its PE Ratio (8.2x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1498's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1498 is good value based on its PB Ratio (0.5x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is PuraPharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PuraPharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has PuraPharm performed over the past 5 years?

-64.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1498 has a large one-off gain of HK$73.0M impacting its December 31 2020 financial results.

Growing Profit Margin: 1498 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 1498 has become profitable over the past 5 years, growing earnings by -64.4% per year.

Accelerating Growth: 1498 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 1498 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).


Return on Equity

High ROE: 1498's Return on Equity (6.2%) is considered low.


Financial Health

How is PuraPharm's financial position?


Financial Position Analysis

Short Term Liabilities: 1498's short term assets (HK$607.7M) exceed its short term liabilities (HK$591.9M).

Long Term Liabilities: 1498's short term assets (HK$607.7M) exceed its long term liabilities (HK$271.0M).


Debt to Equity History and Analysis

Debt Level: 1498's debt to equity ratio (89.6%) is considered high.

Reducing Debt: 1498's debt to equity ratio has increased from 27.3% to 89.6% over the past 5 years.

Debt Coverage: 1498's debt is well covered by operating cash flow (26.2%).

Interest Coverage: Insufficient data to determine if 1498's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is PuraPharm current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1498's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1498's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1498's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1498's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1498 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1498's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Abraham Chan (59 yo)

no data

Tenure

HK$2,902,000

Compensation

Mr. Yu Ling Chan, also known as Abraham, BASc C.Eng. MIStruct E. P.Eng., has been the Chief Executive Officer and Chairman of PuraPharm Corporation Limited. Mr. Chan has been a Director at PuraPharm Corpor...


CEO Compensation Analysis

Compensation vs Market: Abraham's total compensation ($USD373.08K) is above average for companies of similar size in the Hong Kong market ($USD230.70K).

Compensation vs Earnings: Abraham's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1498's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: 1498's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1498 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PuraPharm Corporation Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PuraPharm Corporation Limited
  • Ticker: 1498
  • Exchange: SEHK
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$275.084m
  • Shares outstanding: 392.98m
  • Website: https://www.purapharm.com

Number of Employees


Location

  • PuraPharm Corporation Limited
  • Jardine House
  • Suite 4002
  • Central
  • Hong Kong

Listings


Biography

PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mailand Ch...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:21
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.